Core Lab Capabilities

Rigorous Wet-Lab Optimization

Direct technical intervention across three critical operational pillars to eliminate experimental friction.

01 / Molecular

02 / Assays

03 / Experiment

Construct Design

Method Development

Process & Experimental Design

Sequence-level optimization and vector design to maximize expression yield and minimize construct failure.

Systematic optimization and audits of assay protocols, reagent logistics, and equipment utilization to enable high quality data generation

Process optimization using essential controls for minimizing contamination and producing high quality material.

Advisory Capabilities

Translational Execution for Modality Development

We resolve critical bottlenecks in modality strategy, study design, and CRO selection to accelerate clinical readiness.

04 / Novel Therapies

05 / Durable Therapeutics

RNA Therapeutics

Cell & Gene Therapies

Disease Indications

Passionate about developing durable genetic medicines for curing disease. Experience with both viral and nonviral strategies for cell targeting, gene editing, and protein replacement.

Experience in oncological, infectious, immunological and rare genetic disease, with a deep understanding of biology for diverse indications such as Hemophilia and Systemic Lupus Erythematosus (SLE)

06 / Patient Focused

Experience developing RNA modalities such as small interfering RNAs (siRNAs) and long coding RNAs (mRNA, circRNA, saRNA) for suitable applications. Interest in targeting RNA structure with small molecules and peptides.

Scientific De-risking For Pipeline Assets

Our objective scientific research, validation and market positioning analyses are engineered to de-risk high-stakes biotechnology investments and accelerate translational execution.

07 / Feasibility

08/ IP & Market

09 / Operations

Construct Validation

Technical & Competitive Intelligence

Clinical Feasibility

We perform exhaustive evaluations of molecular construct design, expression platform viability, and experimental protocols to identify potential translational bottlenecks before wet-lab execution.

Our deep-dive mapping of the global therapeutic landscape profiles clinical trials, intellectual property positioning, and platform constraints of potential market competitors.

We provide independent assessments of cold-chain logistics, wet-lab operational capacity, flexibility for CRO usage, and technical documentation preparedness to keep your clinical transition on schedule.

Intelligence Capabilities

Meet the Founder

My passion lies in driving innovation via robust platforms and methods and fostering collaborative environments to create impactful solutions for clients, patients, and communities.

As a scientist, I tackled challenges in RNA biology, sequencing technology, and genetic medicines, and applied the solutions toward diagnostics and treatments for infectious, immunological, and rare diseases. Early in my career, I made key discoveries in the RNA interference pathway, specifically how small RNAs are assembled into effector complexes and are stabilized through RNA modification. As a research scientist at the Broad Institute, I developed methods for next-generation sequencing (NGS) of viral genomes from clinical samples to generate ‘open access’ data from outbreaks of deadly RNA viruses like Ebola. As it was a consortium research endeavor, I was technical lead on the viral genomics team, supporting collaborations with local and international leaders in pandemic response. I continued to develop methods for NGS characterization, specifically for single-cell sequencing and analysis of antigen-specific T Cells at Repertoire Immune Medicines. At GreenLight Biosciences and Orbital Therapeutics, I led platform development teams in RNA genetic medicines, pushing the limit of mRNA modalities by making progress through innovation in RNA architecture, protein durability, and nonviral formulation designs. These genetic medicines required an understanding of disease biology for diverse indications such as Hemophilia, Sickle Cell Disease (SCD), and Systemic Lupus Erythematosus (SLE).

As a biotechnology consultant and advisor, I collaborate with organizations to support experimental and construct design, develop and optimize methods, streamline logistics and operations, prepare technical and competitive intelligence analyses, and provide project guidance.

Christian Matranga, PhD Founder, Advisor & Principal Investigator

Selected Publications

Matranga C, et al, Nucleic acid therapeutics for genetic disorders. US 2022/0096525 A1. patent/US20220096525A1/en

Metsky HC, Siddle KJ, et al, Matranga CB. Capturing sequence diversity in metagenomes with comprehensive and scalable probe design. Nature Biotechnology. 10.1038/s41587-018-0006-x

Andersen KG, Shapiro BJ, Matranga CB, et al, Sabeti PC. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell. 10.1016/j.cell.2015.07.020

Gire SK, et al, Khan SH, Sabeti PC. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 10.1126/science.1259657

Matranga C, Pyle AM. Double-stranded RNA-dependent ATPase DRH-3: insight into its role in RNA silencing in Caenorhabditis elegans. Journal of Biological Chemistry. 10.1074/jbc.M110.117010

Horwich MD, Li C, Matranga C, et al, Zamore PD. The Drosophila RNA methyltransferase, DmHen1, modifies germline piRNAs and single-stranded siRNAs in RISC. Current Biology. 10.1016/j.cub.2007.06.030

Matranga C, et al, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 10.1016/j.cell.2005.08.044

Proven Operational Execution

What Collaborators Are Saying

‘I’ve had the chance to work with Chris Matranga across several stages of my career, first at the Broad Institute, later at GreenLight, and more recently through his role at LeverageBio. Each time, I’ve been struck by his ability to bring clarity, creativity, and a deep sense of purpose to scientific problem solving.

At Flexomics, Chris played a key role in helping us shape the direction of our platform as we prepared to bring it to a broader audience. He offered thoughtful guidance on how to articulate our value proposition, sharpen our translational impact, and position the work in ways that resonate across both scientific and commercial communities. His depth of experience in immunology, genomics, and therapeutic discovery made his contributions particularly valuable as we refined our strategy.

Chris is a true collaborator, always focused on moving the science forward. I’ve greatly appreciated the chance to work with him and wouldn’t hesitate to recommend him to others building transformative technologies in life sciences.’

Magali S, PhD, Co-Founder & CEO

‘The team from LeverageBio was professional and very knowledgeable. They exceeded all deadlines and delivered high quality work.’

Robert L, PhD, Biotechnology Director

‘I've known and worked with Chris first during his time with GreenLight, and now directly at LeverageBio where he has been helping support me as I look for additional technology platforms for my portfolio. I appreciate Chris' expertise, diligence and collaboration in scoping opportunities and deep diving into the technical details to help shape my thinking and provide me with the key information needed to make solid decisions.’

Brian D, PhD, Senior Technologist, NGO

Project Timelines & Deliverables

Flexible timelines and reporting structure enabling efficient transfer of information

Project Timelines

Deliverables

Whether you need a quick burst of strategy to unblock a team or a steady hand for the long haul, project advising timelines are flexible to your goals

• Sprint Advising (2–6 weeks): Built for rapid impact. This timeline focuses on intense diagnostic sessions, quick-win roadmaps, and immediate execution to move through highly specific bottlenecks.

• Long-Term Partnerships (6–12+ months): Built for sustained, strategic evolution. This model establishes a steady operational rhythm—like bi-weekly meetings and quarterly strategy alignment—to safely steer complex, multi-phase initiatives over time.

To set up any project for success, we start by aligning on key deliverables and realistic deadlines so everyone is on the same page from day one. We are completely agnostic when it comes to reporting style and structure—whether you prefer lightweight direct message updates, formal slide decks, or shared tracking boards, we adapt entirely to your team's native workflow. Together, we'll map out a clear reporting structure to keep momentum high, wrapping up major milestones with dedicated meetings to discuss results, review metrics, and map out next steps.

Translational execution for high-stakes molecular development.

Sitemap

About

Blog

Contact

© 2026 LeverageBio, LLC

Construct Design - Wet-Lab Optimization - Technical Intelligence